Compare OPXS & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | CRDL |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.0M | 97.3M |
| IPO Year | N/A | N/A |
| Metric | OPXS | CRDL |
|---|---|---|
| Price | $14.25 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 34.5K | ★ 691.7K |
| Earning Date | 12-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $39,481,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.35 | ★ N/A |
| Revenue Growth | ★ 21.00 | N/A |
| 52 Week Low | $5.36 | $0.77 |
| 52 Week High | $17.76 | $1.59 |
| Indicator | OPXS | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 49.35 |
| Support Level | $13.09 | $0.88 |
| Resistance Level | $15.44 | $1.12 |
| Average True Range (ATR) | 0.84 | 0.08 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 47.31 | 62.50 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, and light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson and Applied Optics Center Dallas and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor and others.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.